ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.411,55
-0,27%
S&P 500
5.321,41
0,25%
US Dollar vs BRL
5,1233
0,00%
Bitcoin
69.973,73
-0,22%
Brent Oil
82,19
-0,31%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Bellicum Pharmaceuticals Inc (BLCM)

  7. Bellicum Pharmaceuticals Inc (BLCM) Notícias

BLCM

Bellicum Pharmaceuticals (BLCM)

Bellicum Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BLCM
DataHoraFonteTítuloCódigoCompanhia
23/02/202415:19Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:BLCMBellicum Pharmaceuticals Inc
23/02/202415:17Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLCMBellicum Pharmaceuticals Inc
14/02/202420:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BLCMBellicum Pharmaceuticals Inc
30/01/202418:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLCMBellicum Pharmaceuticals Inc
30/05/202317:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BLCMBellicum Pharmaceuticals Inc
11/05/202317:24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BLCMBellicum Pharmaceuticals Inc
05/05/202317:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BLCMBellicum Pharmaceuticals Inc
31/03/202317:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BLCMBellicum Pharmaceuticals Inc
14/03/202317:30GlobeNewswire Inc.Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic AlternativesNASDAQ:BLCMBellicum Pharmaceuticals Inc
16/02/202309:30GlobeNewswire Inc.Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers SymposiumNASDAQ:BLCMBellicum Pharmaceuticals Inc
14/02/202314:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
31/01/202320:43GlobeNewswire Inc.CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BLCMBellicum Pharmaceuticals Inc
31/01/202318:36GlobeNewswire Inc.Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BLCMBellicum Pharmaceuticals Inc
20/01/202316:26Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
19/01/202309:30GlobeNewswire Inc.Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers SymposiumNASDAQ:BLCMBellicum Pharmaceuticals Inc
05/01/202315:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BLCMBellicum Pharmaceuticals Inc
11/12/202212:00GlobeNewswire Inc.Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with RimiducidNASDAQ:BLCMBellicum Pharmaceuticals Inc
18/11/202217:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BLCMBellicum Pharmaceuticals Inc
10/11/202218:05GlobeNewswire Inc.Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
24/10/202217:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
14/10/202217:23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
04/10/202208:30GlobeNewswire Inc.Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the MesaNASDAQ:BLCMBellicum Pharmaceuticals Inc
01/09/202208:30GlobeNewswire Inc.Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:BLCMBellicum Pharmaceuticals Inc
11/08/202217:14Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BLCMBellicum Pharmaceuticals Inc
11/08/202217:02GlobeNewswire Inc.Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
24/05/202207:09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BLCMBellicum Pharmaceuticals Inc
13/05/202217:15Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BLCMBellicum Pharmaceuticals Inc
12/05/202217:05GlobeNewswire Inc.Bellicum Reports First Quarter 2022 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
29/04/202217:35Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
24/03/202217:05GlobeNewswire Inc.Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BLCM

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BEEF3
MINERVA ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados